Throughout 2025, the Russian retail veterinary drug market demonstrated steady growth, with both value and physical sales volumes increasing. Stagnation was recorded only in April (compared to April 2024); in the remaining months, growth rates were characterized by double-digit figures. Over 2025, more than 276.8 million minimum dosage units (MDU) of veterinary drugs were sold in retail (including marketplaces), exceeding 2024 figures by 13.2%. The ruble value of the veterinary retail market increased by 17.7% over the year, reaching RUB 49.2 billion (at retail prices, including VAT). In January 2026, sales growth for animal drugs continued; compared to the first month of 2025, the market grew by 5.6% in rubles and 13.2% in MDU.

The early onset of the season in 2025, caused by a temperature anomaly at the end of winter, led to a shift in consumer activity to the beginning of March. Consequently, April sales figures were 3.7% lower than in April 2024, although the physical sales volume remained stable, with dynamics in MDU at 0.3%.

The trend of import substitution by domestic veterinary drug manufacturers continues in the market. According to the database "Retail Audit of Veterinary Drug Sales in Russia (total sell out)" from the analytical company RNC Pharma, the share of domestic products in the past year was recorded at 56% in monetary terms, and at the beginning of the current year it even exceeded 59%. At the same time, the physical sales volume of Russian drugs reached 74%. In 2025, the growth driver was primarily domestic veterinary drugs; compared to 2024, sales of Russian products increased by 37% in rubles and 26% in physical units. Meanwhile, imported animal drugs are losing their positions, with the market stagnating in monetary terms (-0.2%) and declining by 11.3% in MDU. In January 2026, the decline in demand for foreign products continued, alongside confident growth in the consumption of domestic veterinary drugs. Over the month, Russians purchased 15.2 million MDU of domestically produced products worth RUB 1.8 billion, with sales dynamics recorded at +24% in rubles and +18% in MDU compared to January of the previous year.

It is noteworthy that while at the beginning of the past year, the leaders in consumer spending were ectoparasitic and anthelmintic drugs such as Simparica (Zoetis), Bravecto (MSD), and Inspector (Ekoprom), in January 2026, the top spot was taken over by the Russian dog vaccine drug Mul'tikan (Vetbiokhim). Demand for the vaccine was quite high throughout the past year, with monthly sales volumes exceeding 200,000 MDU. However, the peak demand for the drug occurred in April, when buyers purchased 369,000 physical units of the vaccine, spending almost RUB 205 million. The sharp increase in demand for domestic products in the spring of the past year was also influenced by a new ectoparasitic drug from the company Vetfarmstandart under the brand Tixfli. In April, this product ranked fourth among all veterinary drugs by sales share in rubles. Nevertheless, based on the results of 2025, the lead in total spending by Russian buyers is still held by Simparica, accounting for nearly 8% of all ruble sales in retail. Furthermore, the likely resumption of official sales of Bravecto from MSD adds intrigue to the overall balance of power for the current year.

Fig. Monthly Sales Volume of Domestic and Imported Veterinary Drugs on the Russian Retail Market (including marketplaces) in January 2024 — January 2026, RUB billion, at retail prices, including VAT